Physician profile
Michael A Imevbore
NPI 1679660021
$322,697.19
in general payments reported to CMS, 2019-2025
36 companies · $60K in 2025
The $60K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $25K · 2021: $53K · 2022: $61K · 2023: $42K · 2024: $35K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120K · Food and Beverage: $9,416 · Travel and Lodging: $4,445 · Consulting Fee: $2,448 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120,109.00 |
| Food and Beverage | $9,416.39 |
| Travel and Lodging | $4,445.15 |
| Consulting Fee | $2,448.00 |
| Education | $186.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $210,416.06 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $70,538.87 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $27,400.15 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $5,061.18 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $2,331.55 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,071.32 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Harmony Biosciences LLC | $520.56 | 2020-2024 | |
| Genentech USA, INC. | $495.49 | 2019-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $483.53 | 2020-2024 | Glassia |
| Mylan Specialty L.P. | $390.04 | 2019-2024 | Yupelri |
| Inspire Medical Systems, INC. | $368.15 | 2021-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $287.78 | 2019-2024 | Dupixent |
| Pfizer INC. | $283.76 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $236.06 | 2020-2022 | |
| Amgen INC. | $190.09 | 2022-2025 | Tezspire |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $149.46 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $146.96 | 2020-2021 | |
| Grifols USA, LLC | $145.14 | 2019 | |
| Sunovion Pharmaceuticals INC. | $134.67 | 2019 | |
| Electromed, INC. | $118.49 | 2019-2022 | |
| Insmed, INC. | $117.44 | 2019-2025 | Arikayce |
| Avadel Cns Pharmaceuticals, LLC | $113.42 | 2024-2025 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $104.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Advanced Respiratory, INC | $84.02 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $68.94 | 2021-2022 | |
| Shire North American Group INC | $67.36 | 2019 | |
| Lilly USA, LLC | $60.62 | 2025 | Zepbound |
| Baxter Healthcare | $45.01 | 2022 | |
| Mallinckrodt Enterprises LLC | $42.21 | 2019 | |
| Optinose US, INC. | $24.63 | 2022 | |
| Pulmonx Corporation | $23.48 | 2022 | |
| Covis Pharma Gmbh | $21.30 | 2022 | |
| United Therapeutics Corporation | $20.90 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.18 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Imevbore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.